MedTrace Logo

Evaluation of Treatment Response With Integrated MRI/PET in Patients With Hepatocellular Carcinoma

NCT02550613 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2017-05-16

No results posted yet for this study

Summary

The purpose of this study is to explore the ability of integrated MRI/PET to detect and evaluate treatment outcome in HCC patients.

Conditions

Interventions

DEVICE

The imaging biomarkers determined by MR-PET

The purpose of this study is to explore the ability of integrated MRI/PET to detect and evaluate treatment outcome in HCC patients. This study using 18F-FDG PET and functional MRI (DCE-MRI, Diffusion-weighted MRI, MR spectroscopy).

Sponsors & Collaborators

  • National Taiwan University Hospital

    lead OTHER

Principal Investigators

  • Bang-Bin Chen, MD · Department of Medical Imaging, National Taiwan University Hospital

Eligibility

Min Age
20 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-05-31
Primary Completion
2018-04-30
Completion
2018-04-30

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02550613 on ClinicalTrials.gov